Cardiovascular Today—April 2, 2026

This week’s Cardiovascular update highlights regulatory approvals, device innovation, AI-enabled care advancements, and emerging clinical and observational data across heart disease and transplant care.

In Today’s Newsletter

Dive deeper

🫀 Watchman FLX matches blood thinners in AF [1] [US • 30 Mar 2026]

https://cardiovascularnews.com/laa-closure-blood-thinners-champion-af-acc-2026/
Context: The trial enrolled patients with non-valvular atrial fibrillation who were suitable for long-term anticoagulation.
Key point: Boston Scientific’s Watchman FLX was non-inferior to oral anticoagulation for all-cause stroke, cardiovascular death, and systemic embolism at three years in CHAMPION-AF.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 CVAUSA rolls out Heartflow across its network [2] [US • 24 Mar 2026]

https://www.prnewswire.com/news-releases/cvausa-offers-heartflow-technology-to-elevate-cardiovascular-diagnostics-across-its-expansive-network-302723612.html
Context: The company said the network includes 460+ cardiovascular physicians, 600 providers, and 100+ clinics across eight states.
Key point: Cardiovascular Associates of America (CVAUSA) said it will implement Heartflow’s AI-enabled coronary CT analysis platform across its network.
Implication: Signals pipeline investment and modality expansion.

🧠 FFRangio meets non-inferiority in ALL-RISE [3] [US • 30 Mar 2026]

https://cardiovascularnews.com/performance-of-ai-powered-physiologic-assessment-tool-shows-promise-in-all-rise-trial/
Context: The randomised trial enrolled 1,930 patients across 59 sites, and also reported reduced radiation, less contrast use, and shorter procedure times.
Key point: CathWorks FFRangio performed similarly to invasive pressure-wire guidance for one-year major adverse cardiac events in ALL-RISE.
Implication: May influence prescriber choice and payer reviews pending full data.

📈 CAAS vFFR validates angiography-based lesion assessment [4] [US • 30 Mar 2026]

https://cardiovascularnews.com/fast-iii-confirms-non-inferiority-of-vffr-to-wire-based-lesion-assessment/
Context: The open-label multicentre trial enrolled 2,235 patients with intermediate coronary lesions and used a one-year composite endpoint.
Key point: Pie Medical’s CAAS vFFR was non-inferior to pressure-wire FFR for guiding coronary revascularisation in FAST III.
Implication: May influence prescriber choice and payer reviews pending full data.

🛡️ Emboliner and Sentinel post similar 30-day TAVI outcomes [5] [US • 31 Mar 2026]

https://cardiovascularnews.com/clinical-trial-finds-comparable-performance-between-tavi-embolic-protection-devices/
Context: The 522-patient study ran in the US, Germany, and Brazil, and reported similar stroke rates, with Emboliner capturing more debris.
Key point: Emboline’s investigational Emboliner and Boston Scientific’s Sentinel showed comparable 30-day performance in PROTECT H2H.
Implication: May influence prescriber choice and payer reviews pending full data.

🗣️ Noah Labs earns FDA breakthrough tag for voice AI in heart failure [6] [US • 27 Mar 2026]

https://cardiovascularbusiness.com/topics/clinical/heart-failure/fda-sees-promise-voice-based-ai-model-heart-failure
Context: The company said the algorithm analyses five-second daily voice clips and was trained on more than three million samples.
Key point: Noah Labs Vox received FDA breakthrough device designation for voice-based heart failure monitoring.
Implication: Could inform practice and payer discussions, interpretation depends on study design and confounding control.

💉 Repatha subgroup analysis extends primary prevention case [7] [US • 28 Mar 2026]

https://www.amgen.com/newsroom/press-releases/2026/03/repatha-cuts-risk-of-first-major-cardiovascular-events-by-31-in-highrisk-patients-without-known-significant-atherosclerosis
Context: The subgroup included 3,655 patients followed for a median of 4.8 years, according to the company.
Key point: Amgen said Repatha reduced first major cardiovascular events in a VESALIUS-CV subgroup of high-risk patients without known significant atherosclerosis, all with diabetes.
Implication: May influence prescriber choice and payer reviews pending full data.

⌚ AstraZeneca completes wearable heart failure study [8] [26 Mar 2026]

https://www.theglobeandmail.com/investing/markets/stocks/AZN-N/pressreleases/987363/astrazeneca-completes-heart-failure-wearable-study-boosting-its-digital-health-edge/
Context: The study aimed to develop remote, multidomain digital endpoints for future heart failure trials and real-world monitoring.
Key point: AstraZeneca’s observational wearable ECG patch study in patients recovering from acute decompensated heart failure was marked completed.
Implication: Access programs may expand screening, initiation, and follow-up at scale.

Why it matters

AI-assisted coronary physiology moved closer to routine cath-lab use, with both FFRangio and CAAS vFFR reporting non-inferiority versus wire-based approaches.
Device-based alternatives continued to press into established workflows, from LAA closure in atrial fibrillation to embolic protection during TAVI.
Heart failure monitoring is becoming more remote and data-rich, with voice AI and wearable ECG approaches advancing in parallel.
Large-network implementation matters as much as trial data, shown by CVAUSA’s Heartflow rollout across a broad outpatient footprint.
Lipid management remains active in earlier-risk populations, with Amgen pushing a stronger primary prevention narrative for evolocumab.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

🎯 Catch up on the Top Cardiovascular news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What did CHAMPION-AF show for Watchman FLX and anticoagulants?

Boston Scientific’s Watchman FLX was reported as non-inferior to oral anticoagulation for a three-year composite of stroke, cardiovascular death, and systemic embolism in eligible AF patients. The source also reported less major and non-major non-procedural bleeding. [1]

How important are ALL-RISE and FAST III for cath-lab workflow?

CathWorks FFRangio [3] and Pie Medical CAAS vFFR [4] both matched wire-based physiology on headline clinical outcomes. The sources also highlight workflow gains such as shorter procedures, less contrast, or less invasive assessment. [3][4]

Did PROTECT H2H establish a better embolic protection device for TAVI?

Not on 30-day clinical outcomes. The trial reported similar primary endpoint and stroke rates for Emboline’s Emboliner and Boston Scientific’s Sentinel, although Emboliner captured more debris. [5]

What does FDA breakthrough designation mean for Noah Labs Vox?

It signals regulatory recognition that the device may address an important unmet need, but it is not the same as market clearance or approval. Noah Labs said a new clinical trial is being prepared. [6]

What is new in the Repatha update versus prior VESALIUS-CV reporting?

Amgen highlighted a subgroup of 3,655 high-risk patients without known significant atherosclerosis, all with diabetes, and reported a reduction in first major cardiovascular events. This is a subgroup analysis, not a new standalone outcomes trial. [7]

Why does AstraZeneca’s wearable study matter if it was observational?

Because it focuses on building remote digital endpoints for heart failure recovery after discharge. Even without a control arm, it may help shape future trial design and remote monitoring strategies. [8]

Entities / Keywords

Watchman FLX: Boston Scientific, LAA closure, left atrial appendage closure, CHAMPION-AF, atrial fibrillation, anticoagulation
Heartflow One: Heartflow FFRCT, Heartflow Plaque Analysis, CCTA, CVAUSA, coronary artery disease
FFRangio: CathWorks, ALL-RISE, angiography-derived physiology, PCI, invasive pressure wire
CAAS vFFR: Pie Medical, FAST III, vessel fractional flow reserve, coronary physiology, revascularisation guidance
Emboliner: Emboline, Sentinel, Boston Scientific, PROTECT H2H, TAVI, embolic protection
Noah Labs Vox: heart failure, voice AI, FDA breakthrough device designation, remote monitoring
Repatha (evolocumab): Amgen, PCSK9 inhibitor, VESALIUS-CV, LDL-C, primary prevention
AstraZeneca wearable study: acute decompensated heart failure, ECG patch, digital endpoints, remote monitoring